Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.71 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.71 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.53 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.53 |
| ▸ | PRCP | P42785 | 7/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29866456 | 1.00 | TSHR (0.71) | TSHRNPSR1SLC6A2SLC6A4PRCP | |
| SCHEMBL16303077 | 1.00 | TSHR (0.71) | TSHRNPSR1SLC6A2SLC6A4PRCP | |
| Hydrochloric Acid SCHEMBL15569335 | 0.98 | TSHR (0.73) | TSHRNPSR1SLC6A2SLC6A4PRCP | |
| SCHEMBL1388248 | 0.88 | TSHR (0.73) | TSHRNPSR1SLC6A2SLC6A4PRCP | |
| SCHEMBL4022286 | 0.86 | TSHR (0.75) | TSHRNPSR1SLC6A2SLC6A4PRCP | |
| SCHEMBL18066412 | 0.85 | TSHR (0.69) | TSHRNPSR1SLC6A2SLC6A4PRCP | |
| SCHEMBL18066409 | 0.85 | TSHR (0.69) | TSHRNPSR1SLC6A2SLC6A4PRCP | |
| Potassium Ion SCHEMBL18066427 | 0.85 | TSHR (0.69) | TSHRNPSR1SLC6A2SLC6A4PRCP | |
| Potassium Ion SCHEMBL18066431 | 0.85 | TSHR (0.69) | TSHRNPSR1SLC6A2SLC6A4PRCP | |
| SCHEMBL514422 | 0.84 | TSHR (0.97) | TSHRNPSR1SLC6A2SLC6A4PRCP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 175 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118221637-A | Preparation method and application of tetrahydroisoquinoline amide derivatives | 浙江省化工研究院有限公司 | 2024-06-21 | — | — | CN | claimed |
| WO-2018047983-A1 | INDANE DERIVATIVES USEFUL AS MODULATORS OF MGLUR7 | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-03-15 | — | — | WO | claimed |
| CN-105228996-B | Tetrahydroisoquinolines containing substituted azoles as factor XIa inhibitors | 百时美施贵宝公司 | 2017-11-28 | — | — | CN | claimed |
| CN-107151245-A | A kind of preparation method of levo-praziquantel | 苏州同力生物医药有限公司 | 2017-09-12 | — | — | CN | claimed |
| CN-104540806-B | Azaheterocycles as BIR2 and/or BIR3 inhibitors | 霍夫曼-拉罗奇有限公司 | 2017-05-03 | — | — | CN | claimed |
| CN-103987697-B | Substituted tetrahydroisoquinoline compounds as factor XIA inhibitors | 百时美施贵宝公司 | 2017-04-26 | — | — | CN | claimed |
| EP-1432691-A1 | IMIDAZOLE-4-CARBOXAMIDE DERIVATIVES, PREPARATION AND USE THEREOF FOR TREATMENT OF OBESITY | Bayer Pharmaceuticals Corporation (US) | 2004-06-30 | — | — | EP | claimed |
| WO-2003040107-A1 | IMIDAZOLE-4-CARBOXAMIDE DERIVATIVES, PREPARATION AND USE THEREOF FOR TREATMENT OF OBESITY | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-05-15 | — | — | WO | claimed |
| CN-121494783-B | Tetrahydroisoquinoline amide derivatives and uses thereof | ANHUI AGRICULTURAL UNIVERSITY (CN) | 2026-05-26 | — | — | CN | disclosed |
| CN-121494783-B | Tetrahydroisoquinoline amide derivatives and uses thereof | ANHUI AGRICULTURAL UNIVERSITY (CN) | 2026-05-26 | — | — | CN | disclosed |
| CN-122059926-A | Heterocyclic degradation determinants for target protein degradation | C4医药公司 | 2026-05-19 | — | — | CN | disclosed |
| US-12605450-B2 | C3-carbon linked glutarimide Degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| EP-4717317-A2 | N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION | C4 Therapeutics, Inc. (US) | 2026-04-01 | — | — | EP | disclosed |
| US-12570626-B2 | Degraders and degrons for targeted protein degradation | C4 THERAPEUTICS, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-5232928-A | Elastase inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 1993-08-03 | — | — | US | disclosed |
| US-5232928-A | Elastase inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 1993-08-03 | — | — | US | disclosed |
| EP-0552158-A1 | DERIVATIVES OF ASPARTIC ACID AND GLUTAMIC ACID HAVING ANTI-CHOLECYSTOKININ ACTIVITY. | BLACK JAMES FOUNDATION (GB) | 1993-07-28 | — | — | EP | disclosed |
| WO-1992000958-A1 | DERIVATIVES OF ASPARTIC ACID AND GLUTAMIC ACID HAVING ANTI-CHOLECYSTOKININ ACTIVITY | JAMES BLACK FOUNDATION LIMITED (GB) | 1992-01-23 | — | — | WO | disclosed |
| EP-0232569-B1 | 1-BENZYL-2-(N-SUBSTITUTED)-CARBAMOYL-TETRAHYDROISOQUINOLINES AND METHOD FOR THE PREPARATION THEREOF | T P O "PHARMACHIM" (BG) | 1990-03-14 | — | — | EP | disclosed |
| EP-0232569-A1 | 1-Benzyl-2-(N-substituted)-carbamoyl-tetrahydroisoquinolines and method for the preparation thereof | T P O "PHARMACHIM" (BG) | 1987-08-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12605450-B2 | C3-carbon linked glutarimide Degronimers for target protein degradation | NEDD4, UBE3A, UBE3C | TSHR 174/4885NPSR1 1307/4885SLC6A2 3331/4885 |
| US-12570626-B2 | Degraders and degrons for targeted protein degradation | ADRM1, UCHL3, USP30 | TSHR 380/4885NPSR1 448/4885SLC6A2 3566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.